image: Longevity pioneer Rejuve.Bio announced as sponsor of Aging Research & Drug Discovery Meeting (ARDD 2025), the world's largest meeting in aging research
Credit: Rejuve.Bio
News, 7 August 2025: Rejuve.Bio, the BioAI company pioneering a neural-symbolic AI‑driven co-scientist platform aimed at accelerating drug discovery for extending human healthspan and targeting age‑associated diseases will sponsor the Aging Research & Drug Discovery Meeting (ARDD 2025), the world's largest biopharmaceutical industry conference on aging research.
Aging population requires new scientific advancements
According to the United Nations, the proportion of people aged over 65 now outnumber children younger than five. The enormous growth in the elderly population is posing a socioeconomic challenge to societies worldwide, and necessitates new sweeping interventions for age-associated diseases. Now in its twelfth year, Aging Research and Drug Discovery Meeting will see the world’s brightest leaders in the biopharmaceutical industry gather to showcase the latest innovations into aging research.
Taking place at the Ceremonial Hall, University of Copenhagen, and online from August 25 to 29th, the conference will showcase the latest scientific insights into aging medicine and reveal new advancements to help everyone live a healthier and longer life.
“At Rejuve.Bio, we believe that the future of medicine lies in extending not just lifespan, but healthspan, enabling longer, healthier lives for all. We’re proud to support ARDD 2025, a vital platform uniting world-class researchers, clinicians, and innovators in the pursuit of groundbreaking solutions to age-related disease. Together, we are advancing the science of longevity and turning possibility into progress” said Kennedy Schaal, CEO and Founder, Rejuve.Bio.
Unique networking and collaboration opportunities
ARDD has grown to become the most important conference in longevity biotechnology. Each year, the event provides unique opportunities to connect with a unique mix of academic luminaries, biotech innovators, investors, top pharmaceutical executives, physicians, and related healthcare professionals to discuss the latest advancements in aging research.
“We are extremely honored to host Professors Meldal and Levitt at ARDD2025. Their Nobel prize winning discoveries have been instrumental for drug development and molecular design in part through modelling of proteins and molecules, and in part through the ability to easily create new molecules. It is therefore a great pleasure that they are joining our conference.” said Morten Scheibye-Knudsen, MD, Ph.D., University of Copenhagen.
“We are really excited for ARDD2025, especially with Nobel Laureates Morten Meldal and Michael Levitt joining us. Their contributions have had a lasting impact on drug discovery, and having them at the conference is sure to make it an unforgettable experience.” said Daniela Bakula, Ph.D., University of Copenhagen.
“For 12 years, the Aging Research and Drug Discovery (ARDD) forum grew in size and in quality. It became the world’s main platform for academia-pharma-startup-investor partnership and dialogue. In 2025, the conference will feature the Nobel laureates, pharmaceutical industry executives and healthcare delivery leaders. ARDD is a unique platform for advancing longevity biotechnology around the world.” said Alex Zhavoronkov, Ph.D., founder and CEO of Insilico Medicine.
“At ARDD we strive to highlight the cutting-edge research and clinical applications in a new discipline of healthy longevity medicine. Having Nobel laureates join and speak at the ARDD conference underscores the critical importance of grounding longevity science and medicine in evidence-based, scientifically rigorous approaches.” said Prof.Dr.Evelyne Bischof, the organizer of the Longevity Medicine Days.
Aging research has become a great platform for advancing drug discovery with blockbuster potential, with pharmaceutical leaders like Novartis, Biogen, and Eli Lilly actively supporting this transformative field. ARDD has established itself as the go-to venue where scientists and pharma companies collaborate, share insights, and launch aging-focused research initiatives. In 2024, industry leaders such as Eli Lilly, Novartis, Regeneron, Biogen, and Lundbeck presented their latest research at ARDD, highlighting the meeting's pivotal role in advancing healthspan and longevity science. Be part of ARDD 2025 and contribute to shaping the future of medicine.
For further information, images or interviews, please contact:
About Aging Research for Drug Discovery Conference
At ARDD, leaders in the aging, longevity, and drug discovery field will describe the latest progress in the molecular, cellular and organismal basis of aging and the search for interventions. Furthermore, the meeting will include opinion leaders in AI to discuss the latest advances of this technology in the biopharmaceutical sector and how this can be applied to interventions. Notably, this year we will have a special day called Longevity Medicine Day, specifically for physicians where the leading-edge knowledge of clinical interventions for healthy longevity will be described. ARRD intends to bridge clinical, academic and commercial research and foster collaborations that will result in practical solutions to one of humanity's most challenging problems: aging. Our quest to extend the healthy lifespan of everyone on the planet.